Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16982451 | 0.87 | ALDH1A1 (0.67) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL12312156 | 0.85 | ALDH1A1 (0.71) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL29833145 | 0.85 | ALDH1A1 (0.71) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL6782848 | 0.84 | ALDH1A1 (0.57) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL6780707 | 0.81 | KDM4E (0.61) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL16982411 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL29979942 | 0.79 | AR (0.58) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL2978081 | 0.79 | AR (0.58) | ALDH1A1SMN1; SMN2KMT2AMEN1HPGD | |
| SCHEMBL16982486 | 0.79 | ALDH1A1 (0.61) | ALDH1A1KDM4EGAALMNASMN1; SMN2 | |
| SCHEMBL13161889 | 0.79 | ALDH1A1 (0.68) | ALDH1A1KDM4EGAALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1359917-B1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6821969-B2 | FOR THERAPY AND PROPHYLAXIS OF HERPESVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY | 2004-11-23 | — | — | US | disclosed |
| EP-1359917-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1220858-B1 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | UPJOHN CO (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002064145-A1 | THIOXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1220858-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-10 | — | — | EP | disclosed |
| US-6340680-B1 | AS ANTIVIRAL AGENTS, AGAINST VIRUSES OF HERPES FAMILY | PHARMACIA AND UPJOHN COMPANY | 2002-01-22 | — | — | US | disclosed |
| WO-2001025239-A2 | OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143013-A1 | Thioxazinoquinolones as antiviral agents | DDX5, IRF3, ZC3HAV1 | ALDH1A1 858/4885KDM4E 1053/4885GAA 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.